NASDAQ · Key Statistics

Syndax Pharmaceuticals, Inc. (SNDX) P/E Ratio, ROE & Key Statistics

$8.56 NASDAQ: SNDX Market Cap $770.64M

Data as of Nov 18, 2026 close · Source: Financial Modeling Prep (methodology)

Every valuation, profitability, balance-sheet and per-share figure DeltaScreener holds for Syndax Pharmaceuticals, Inc. (SNDX), each with what it measures. Figures are trailing twelve months or the most recent reported period.

Valuation

MetricValue
P/E ratioShare price divided by earnings per share.-3.85
P/B ratioShare price divided by book value per share.-47.72
P/S ratioMarket value divided by annual revenue.2.84
PEG ratioP/E divided by the earnings growth rate.-0.09
EV / EBITDAEnterprise value against earnings before interest, tax, depreciation and amortisation.-10.69
EV / RevenueEnterprise value against annual revenue.4.41
Earnings yieldEarnings per share as a percentage of the share price — the inverse of P/E.-14.33%
Free cash flow yieldFree cash flow as a percentage of market value.-21.59%

Profitability

MetricValue
Gross marginRevenue left after the direct cost of goods sold.93.69%
Operating marginRevenue left after operating costs.-61.72%
Net marginRevenue left after every cost, including tax and interest.-72.38%
Return on equityProfit as a percentage of shareholders’ equity.-804.38%
Return on assetsProfit as a percentage of total assets.-30.24%
Return on capital employedOperating profit against the capital the business uses.-31.25%

Financial health

MetricValue
Current ratioCurrent assets divided by current liabilities. Above 1 means short-term assets cover short-term bills.4.69
Quick ratioThe same, excluding inventory.4.37
Cash ratioCash alone against current liabilities.1.13
Debt to equityTotal borrowings against shareholders’ equity.-34.31
Debt to assetsTotal borrowings against total assets.0.65
Interest coverageHow many times operating profit covers the interest bill.-1.98

Per share and size

MetricValue
Earnings per shareProfit attributable to each share.−$3.29
Market capitalisationShare price times shares outstanding.$770.64M
Enterprise valueMarket value plus net debt — what it would cost to buy the business outright.$859.96M

Dividend

MetricValue
Dividend yieldAnnual dividend as a percentage of the share price.0.00%

Syndax Pharmaceuticals, Inc. (SNDX) statistics — frequently asked questions

What is Syndax Pharmaceuticals, Inc.'s P/E ratio?

Syndax Pharmaceuticals, Inc. (SNDX) trades on a price-to-earnings ratio of -3.85. A negative P/E means the company reported a loss, so the ratio is not a meaningful valuation measure.

What is Syndax Pharmaceuticals, Inc.'s return on equity?

Syndax Pharmaceuticals, Inc. (SNDX) reports a return on equity of -804.38%, meaning it generated that much profit for every dollar of shareholders' equity.

How much debt does Syndax Pharmaceuticals, Inc. carry?

Syndax Pharmaceuticals, Inc. (SNDX) has a debt-to-equity ratio of -34.31, which compares total borrowings with shareholders' equity.

What is Syndax Pharmaceuticals, Inc.'s profit margin?

Syndax Pharmaceuticals, Inc. (SNDX) keeps -72.38% of revenue as net profit after every cost, including tax and interest.

P/E and ROE of other Biotechnology stocks

VRTX P/E 34.56REGN P/E 19.22MRNA ROE -37.62%RVMD ROE -91.93%ROIV ROE -6.12%INSM ROE -82.75%UTHR P/E 21.31INCY P/E 55.62ALNY P/E 36.02ASND P/E 17.60All Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.